[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].

Abstract

OBJECTIVE:

To investigate the therapeutic efficacy and side effects of treating patients with myelodysplastic syndrome-RAEB (MDS-RAEB) and with refractory acute myeloid leukemia (AML) by using decitabine combined with CAG regimen.

METHODS:

Clinical data of 21 patients with MDS-RAEB or refractory AML from July 2011 to July 2014 were analyzed retrospectively. Among 21 patients there were 4 cases of MDS-RAEB and 17 cases of refractory AML; 12 cases were beyond 60 years old; 13 cases had high-risk karyotypes. All the patients received decitabine combined with CAG regimen consisting of decitabine 20 mg/(m(2) · d), d 1-5; aclarubicin 10 mg/d, d 6-13; cytarabine 20 mg/d, d 6-19; G-CSF 300 µg/d, d 6-19.

RESULTS:

After 1 cycle of treatment with DCAG regimen, the outcome of 21 patients showed that 8 cases achieved complete remission (42.1%), 8 cases achieved partial remission (42.1%), 2 cases achieved hematologic improvement, 1 cases achieved non-remission and 2 cases died; and the 1 year overall survival rate was 67.5%. The outcome of 12 patients beyond 60 years old showed that 6 cases achieved complete renission (60%, 6/10), and the 1 year overall survival rate was 62.5%. The outcome of 13 patients with high-risk karytype showed that 6 cases achieved complete renission (54.5%, 6/11), and the 1 year overall survival rate was 61.5%. The main adverse event was myelosuppression, and non-hematological toxicity included liver dysfunction and gastrointestinal tract reaction.

CONCLUSION:

Decitabine combined with CAG regimen is effective and safe for treatment of MDS-RAEB and refractory AML patients, which can prolong lives of patiens with refractory hematological diseases.

• Authors: Xue-Liang Yang, Ya-Mei Wu, Yong-Bin Cao, Xiao-Hong Li, Li-Xin Xu, Zhou-Yang Liu, Bei Liu, Bei Yan, Song-Wei Li, Wan-Ming DA, Xiao-Xiong Wu
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 23 Issue 4 Pg. 1056-61 (Aug 2015) ISSN: 1009-2137 [Print] China
• PMID: 26314446 (Publication Type: Journal Article)

Chemical References

• aclacinomycins
• Cytarabine
• Granulocyte Colony-Stimulating Factor
• Aclarubicin
• Decitabine
• Azacitidine

Topics

• Aclarubicin (analogs & derivatives)
• Antineoplastic Combined Chemotherapy Protocols
• Azacitidine (analogs & derivatives)
• Cytarabine
• Decitabine
• Granulocyte Colony-Stimulating Factor
• Humans
• Karyotype
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Pancytopenia
• Recurrence
• Remission Induction
• Retrospective Studies
• Survival Rate
• Treatment Outcome